ALK and lung adenocarcinoma: Significantly more patients were in pretreatment KPS > 70, had lung adenocarcinoma, had the ALK/EGFR mutation, were not synchronous, had extracranial metastases, were supratentorial or multiple, and had no radiotherapy.